Zobrazeno 1 - 10
of 370
pro vyhledávání: '"Bypassing agents"'
Autor:
Antonella Mameli, Francesco Marongiu, Lara Fenu, Maria Filomena Ruberto, Paola Schirru, Simona Cornacchini, Doris Barcellona
Publikováno v:
Turkish Journal of Hematology, Vol 41, Iss 4, Pp 264-270 (2024)
Objective: Acquired hemophilia A (AHA) is a rare autoimmune disease characterized by the presence of autoantibodies against coagulation factor VIII, leading to spontaneous hemorrhage in patients without a prior family or personal history of bleeding.
Externí odkaz:
https://doaj.org/article/fe00f85d315749bba143e542877ea762
Autor:
Tiago Paiva Prudente, Ricardo Mesquita Camelo, Rafael Alves Guimarães, Maria do Rosário Ferraz Roberti
Publikováno v:
São Paulo Medical Journal, Vol 142, Iss 5 (2024)
ABSTRACT BACKGROUND: Until recently, the treatment of people with hemophilia A and inhibitors (PwHAi) was based on the use of bypassing agents (BPA). However, the advent of emicizumab as prophylaxis has demonstrated promising results. OBJECTIVES: We
Externí odkaz:
https://doaj.org/article/f9e32c6c89a04edbb77c927d548a0141
Autor:
Massimo Morfini, Jacopo Agnelli Giacchiello, Erminia Baldacci, Christian Carulli, Giancarlo Castaman, Anna Chiara Giuffrida, Giuseppe Malcangi, Angiola Rocino, Sergio Siragusa, Ezio Zanon
Publikováno v:
Hematology Reports, Vol 15, Iss 2, Pp 384-397 (2023)
The Medical Directors of nine Italian Hemophilia Centers reviewed and discussed the key issues concerning the replacement therapy of hemophilia patients during a one-day consensus conference held in Rome one year ago. Particular attention was paid to
Externí odkaz:
https://doaj.org/article/d24dcae5a7a04163aca7e5a8789dc405
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 18, Iss 1, Pp 1-8 (2023)
Abstract Background Haemophilia A is a bleeding disorder caused by deficiency of coagulation factor VIII (FVIII) which leads to severe and repeated bleedings. There is a need to understand the optimal treatment pathway for FVIII inhibitors with the u
Externí odkaz:
https://doaj.org/article/b852cc8a385c44a29c31e8f118c5f26f
Publikováno v:
Thrombosis Update, Vol 8, Iss , Pp 100111- (2022)
Introduction: Plasma factor X (FX) levels may affect the therapeutic effects of bypass hemostatic therapy among patients with hemophilia with inhibitors. This study aimed to reproduce low and high FX level conditions in vitro and analyze changes in c
Externí odkaz:
https://doaj.org/article/58df2f9630bb48188c5d5850814c3ece
Publikováno v:
Clinical Case Reports, Vol 9, Iss 2, Pp 623-628 (2021)
Abstract Acquired factor V inhibitor represents a rare condition, described only in case reports. The use of activated bypassing agents in bleeding control could be of aid and improve the survival in symptomatic patients with acquired factor V inhibi
Externí odkaz:
https://doaj.org/article/1b871170de314a25b0ad4dd556be9dfc
Autor:
Riccardo Bruna, Riccardo Moia, Alessandra Valpreda, Enrico Dosio, Roberta Rolla, Augusto Federici, Umberto Dianzani, Gianluca Gaidano, Andrea Patriarca
Publikováno v:
Clinical Case Reports, Vol 9, Iss 1, Pp 98-101 (2021)
Abstract This case report highlights the challenges in controlling bleeding and correcting coagulation tests through the use of bypassing agents in patients with FV inhibitors.
Externí odkaz:
https://doaj.org/article/7bd23d4cab9c4b1ba10d3d34d35396b3
Autor:
C. Hermans, P. L. F. Giangrande, B. O’Mahony, P. de Kleijn, M. Bedford, A. Batorova, J. Blatný, K. Jansone, on behalf of the European Haemophilia Consortium (EHC) and the European Association for Haemophilia and Allied Disorders (EAHAD)
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 15, Iss 1, Pp 1-4 (2020)
Externí odkaz:
https://doaj.org/article/deb6e840044643fa83146b5f6f15db0d
Publikováno v:
Global Journal on Quality and Safety in Healthcare, Pp 38-43 (2020)
Introduction: Medication-use evaluation (MUE) is a performance improvement method used to achieve optimal patient outcomes. The recombinant human factor VIIa (rFVIIa) (NovoSeven) is an expensive agent approved by the U.S. Food and Drug Administration
Externí odkaz:
https://doaj.org/article/bdf47be186744e969ebf0e810c4fe687
Autor:
Melen Brinza, Uscatescu Valentina, Gheorghe Georgiana, Chiriac Elisabeta, Ciobanu Claudia, Orban Horia, Coriu Daniel
Publikováno v:
Romanian Journal of Laboratory Medicine, Vol 28, Iss 2, Pp 217-224 (2020)
The development of factor VIII inhibitors (allo-antibodies) continues to be a major complication in the management of severe forms of hemophilia A, especially as far as treatment and treatment response monitoring is concerned. The need to implement a
Externí odkaz:
https://doaj.org/article/e9463b5925e345f680f2f55143c8f598